Surfactant TA, developed in Japan (TokyoTanabe), is extracted from homogenised cow lungs.2' To achieve optimum physical prop-erties, dipalmitoylphosphatidylcholine, palmitic acid, and triglyceride are added. It contains 48% dipalmitoylphosphatidylcholine, 16% unsaturated phosphatidylcholine, 4% phosphatidylglycerol, 4% triglyceride, 8% fatty acids, 7% cholesterol, sphingomyelin, and other lipids and 1% apoproteins SpB and SpC. It is freeze dried and when used 100-200 mg is sonicated for five minutes with 3-4 ml saline.
Surfactants
Surfactant TA, developed in Japan (TokyoTanabe), is extracted from homogenised cow lungs.2' To achieve optimum physical prop- erties, dipalmitoylphosphatidylcholine, palmitic acid, and triglyceride are added. It contains 48% dipalmitoylphosphatidylcholine, 16% unsaturated phosphatidylcholine, 4% phosphatidylglycerol, 4% triglyceride, 8% fatty acids, 7% cholesterol, sphingomyelin, and other lipids and 1% apoproteins SpB and SpC. It is freeze dried and when used 100-200 mg is sonicated for five minutes with 3-4 ml saline.
The Japanese surfactant, modified by Abbott laboratories, is called Survanta.79 It is a frozen aqueous suspension of 25 mg/ml and contains approximately 88-90% phospholipids (of which 500/o is disaturated phosphatidylcholine), 3% triglycerides, 6% free fatty acids, 1% protein, and 0-2% cholesterol. It is thawed before use in a dose of 4 ml/kg.
Calf lung surfactant (CLSE) is made by extracting surfactant from calf lungs.'1'3 It contains 90-97% phospholipid of which 85% is phosphatidylcholine (70% disaturated), 6% phosphatidylglycerol, 4% phosphatidylinositol, 3% phosphatidylethanolamine, 1% sphingomyelin, and 5% cholesterol and cholesterol esters, and 1% protein which is mainly low molecular weight apoproteins SpB and SpC. It is sterilised by flash autoclaving. Before use 90 mg are vortexed with 3 ml of saline. Porcine surfactant (Curosurf, Chiesi) is extracted from minced pig lungs. '1-6 Curosurf'5 showed a significant reduction this was a subgroup from the European Curosurf trial,'6 which showed no effect on intraventricular haemorrhage, even grade 3 and 4. Survanta showed no effect in the American trial7 but a significant increase in the European trial. the incidence of pneumothoraces. The rescue trials all produced a reduction in pneumothoraces that were significant except for the European trial of Survanta.8 The prophylactic trials showed a significant reduction in the incidence of pneumothoraces in only two of the trials of CLSE'0 13 and one trial of ALEC powder.25
PATENT DUCTUS ARTERIOSUS
In the first non-randomised trial of Fujiwara et al patent ductus arteriosus occurred in nine out of 10 babies and it looked as though this may be a major side effect of surfactant treatment. 2 Figures 4 and 10 show the incidence of patent ductus arteriosus. In the rescue trials surfactant treatment tended to increase the incidence of patent ductus arteriosus, although this effect was only significant in one trial of Surfactant TA. 6 The trial of Curosurf had a 57% increase in the babies requiring surgical closure or indomethacin treatment in the surfactant treated group."6 In the prophylactic trials none had a significant effect on the incidence. No trial showed a significant reduction in patent ductus arteriosus.
BRONCHOPULMONARY DYSPLASIA
The incidence of bronchopulmonary dysplasia is not reported in all trials. Figures 5 and 11 show that surfactant treatment has a variable effect on the incidence. In the rescue trials only human surfactant showed a significant reduction in one trial. 8 In the prophylactic trials only CLSE'0 " and ALEC25 showed a significant reduction.
CHANGES IN OXYGENATION
All trials have shown a reduction in the oxygen requirements. Figures 6 and 12 show the effect of different surfactant preparations on oxygenation over the first three days, presented as the 
